Use of Vitamin K Antagonist Therapy in Geriatrics: a French National Survey from the French Society of Geriatrics and Gerontology (SFGG)
Overview
Authors
Affiliations
Objective: We aimed to evaluate the quality and determinants of vitamin K antagonists (VKA) control among very elderly patients in geriatric settings.
Methods: A national cross-sectional survey was conducted among patients aged ≥80 years who were hospitalized in rehabilitation care or institutionalized in a nursing home and who were treated by VKA. Time in therapeutic range (TTR) was computed according to Rosendaal's method.
Results: A total of 2,633 patients were included. Mean [± standard deviation (SD)] age was 87.2 ± 4.4 years and 72.9 % were women. The main indication for VKA therapy was atrial fibrillation (AF; 71.4 %). Mean (±SD) TTR was 57.9 ± 40.4 %. After backward logistic regression, poorer VKA control (TTR <50 vs. ≥50 %) was associated with being hospitalized in rehabilitation care [odds ratio (OR)(rehab. vs. nursing home) = 1.41; 95 % CI 1.11-1.80], the indication for VKA treatment (OR(prosthetic heart valve vs. AF) = 4.76; 95 % CI 2.83-8.02), a recent VKA prescription (OR(<1 vs. >12 months) = 1.70; 95 % CI 1.08-2.67), the type of VKA (OR(fluindione vs. warfarin) = 1.22; 95 % CI 1.00-1.49), a history of international normalized ratio >4.5 (OR = 1.50; 95 % CI 1.21-1.84), a history of major bleeding (OR = 1.88; 95 % CI 1.00-3.53), antibiotic use (OR = 1.83; 95 % CI 1.24-2.70), and falls (OR(≥2 falls during the past year vs. <2) = 1.26; 95 % CI 1.01-1.56).
Conclusion: Overall, VKA control remains insufficient in very old patients. Poorer VKA control was associated with taking VKA for a prosthetic heart valve, a recent VKA prescription, the use of other VKAs than warfarin, a history of overcoagulation and major bleeding, antibiotic use, and falls.
Pisica-Donose G, Piccoli M, Genet B, Bouee S, Berechet S, Berechet I PLoS One. 2023; 18(4):e0283604.
PMID: 37014881 PMC: 10072791. DOI: 10.1371/journal.pone.0283604.
Manckoundia P, Rosay C, Menu D, Nuss V, Mihai A, Vovelle J Int J Environ Res Public Health. 2020; 17(18).
PMID: 32937847 PMC: 7558265. DOI: 10.3390/ijerph17186685.
Sikirdji C, Costa D, Alonso S, Clape J, Amouyal M, de Waziere B Intern Med J. 2019; 49(11):1442-1446.
PMID: 31713344 PMC: 6973070. DOI: 10.1111/imj.14626.
Atrial fibrillation in women: treatment.
Ko D, Rahman F, Martins M, Hylek E, Ellinor P, Schnabel R Nat Rev Cardiol. 2016; 14(2):113-124.
PMID: 27786235 PMC: 5520636. DOI: 10.1038/nrcardio.2016.171.
Odashiro K, Yokoyama T, Fukata M, Arita T, Maruyama T, Akashi K J Atheroscler Thromb. 2016; 24(1):68-76.
PMID: 27319745 PMC: 5225134. DOI: 10.5551/jat.35121.